Key Drivers
- Strong Liquidity
- Rising Losses
- Dilution Pressure
AIAI Summary
ADPT is now a cleaner but narrower MRD commercialization story: accelerating MRD adoption and raised 2026 guidance improve visibility, but with Genentech revenue gone, persistent losses/FCF burn, dilution, and a rich ~9x sales valuation, the stock remains a high-execution bet that only works if MRD growth keeps outpacing costs.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Losses
- •Dilution Pressure
ADPT has strong liquidity and solid gross margins, but persistent operating losses, negative cash flow, heavy stock-based compensation, and a demanding valuation continue to outweigh balance-sheet strength.
Price Behavior
Key Price Behavior Insights:
- •Breakout failure
- •Lower closes
- •Mildly oversold
ADPT remains technically weak after closing at a last-month low near $12.83, with broken support and a downward trend dominating despite mildly oversold conditions that could spark a brief bounce.
Broke below the prior $13.50-$14.70 range in early
Sentiment & News
Key News Insights:
- •MRD Growth
- •Insider Selling
- •Earnings Beat
Adaptive Biotechnologies' first-quarter results showed improving MRD adoption and a smaller-than-expected loss, but recurring insider selling by the president/COO remains a notable overhang.
The quarter's operational progress is constructive, but continued executive share sales may temper near-term sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings